Search results
Results for “retatrutide”
Check each result's review status before you open it.
Tip: press / to focus. Press Esc to clear.
What do the evidence levels mean?
These labels give a quick guide. Established means strong evidence supports one defined use. Emerging means studies in people exist, but important questions remain. Insufficient means reliable studies in people are missing or too limited.
21 results for “retatrutide”
Exact names come first.Start with the full review for this peptide.
Read the review →Retatrutide
Still being studied. Late-stage study reports show meaningful results in people, but no product is approved and no regulatory review is complete.
“Retatrutide caused weight loss in a randomized human trial.”
The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.
“Retatrutide is FDA-approved.”
It remains investigational. FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition. Positive trial results and sponsor announcements are not marketing approval.
“Phase 3 trials showed retatrutide produced average weight reduction above 20%.”
Lilly reported average weight reduction of up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3 at 80 weeks. These are sponsor-reported topline efficacy-estimand figures and group averages, not individual outcomes, and no full peer-reviewed report of either trial was available in the records reviewed here.
“The TRIUMPH-3 results show retatrutide prevents cardiovascular events.”
TRIUMPH-3 was not a definitive cardiovascular-outcomes trial. The sponsor reported a hazard ratio of 0.82 (95% CI 0.55 to 1.22) for the five-component major adverse cardiovascular event measure and 1.12 (95% CI 0.64 to 1.96) for the three-component measure. Both intervals include 1.0 and are wide, so studying a molecule in people with cardiovascular disease is not the same as showing it prevents events.
“Retatrutide is being submitted to FDA, so it will be available in 2027.”
Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.
“Research retatrutide sold online is the same as clinical-trial material.”
A matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence. FDA warns that retatrutide products sold directly to consumers as research material are unapproved and of unknown quality.
FDA’s concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
LY3437943 in people with type 2 diabetes: a phase 1b randomized trial
PubMed · The Lancet · Human pharmacology · 2022
Retatrutide for people with type 2 diabetes: a phase 2 randomized trial
PubMed · The Lancet · Randomized trial · 2023
Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial
PubMed · New England Journal of Medicine · Randomized trial · 2023
Retatrutide for metabolic dysfunction-associated steatotic liver disease
PubMed · Nature Medicine · Randomized trial · 2024
TRIUMPH-1 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
TRIUMPH-2 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
TRIUMPH-3 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
TRIUMPH-1 early sponsor-reported results
Eli Lilly and Company · Reference · 2026
TRIUMPH-2 and TRIUMPH-3 early sponsor-reported results
Eli Lilly and Company · Reference · 2026
RETA peptide (retatrutide)
An online nickname for retatrutide (LY3437943), one investigational molecule. The molecule activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. The nickname is not an approved product name and does not show what a product sold online contains or its purity or quality.
Peptides for weight loss: results, medicines, and risks
Learn which peptide medicines help with weight loss, what a direct study found, and which risks matter. Compare approved medicines with other products.
Retatrutide cost and availability: why there is no approved retail product
No retatrutide product is FDA-approved or launched, and no legitimate U.S. retail price exists. The sections below separate research access, expanded access, research sales, compounded claims, and speculation.